OTCMKTS:ARTH - Arch Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.4390 +0.01 (+2.33 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$0.4250
Today's Range$0.4201 - $0.45
52-Week Range$0.25 - $0.89
Volume122,830 shs
Average Volume396,639 shs
Market Capitalization$69.43 million
P/E RatioN/A
Dividend YieldN/A
Beta0.88
Arch Therapeutics logoArch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ARTH
CUSIPN/A
Phone617-431-2313

Debt

Debt-to-Equity RatioN/A
Current Ratio8.82
Quick Ratio8.82

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book43.90

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-211.54%
Return on Assets-109.06%

Miscellaneous

Employees10
Outstanding Shares159,600,000
Market Cap$69.43

Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics Inc (OTCMKTS:ARTH) released its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.01). View Arch Therapeutics' Earnings History.

What price target have analysts set for ARTH?

3 equities research analysts have issued 12-month price targets for Arch Therapeutics' shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Arch Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 583.4% from the stock's current price. View Analyst Ratings for Arch Therapeutics.

What is the consensus analysts' recommendation for Arch Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Arch Therapeutics' key competitors?

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the folowing people:
  • Dr. Terrence W. Norchi M.D., Co-Founder, Pres, CEO & Director (Age 53)
  • Mr. Richard E. Davis, CFO, Principal Accounting Officer & Treasurer (Age 60)
  • Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific Advisor
  • Dr. Steven A. Kates Ph.D., VP of Technology
  • Dr. William Tzocor Denman M.D., MBChB,FRCA, IV, Clinical Advisor (Age 55)

Has Arch Therapeutics been receiving favorable news coverage?

News coverage about ARTH stock has been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arch Therapeutics earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.4390.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $69.43 million. Arch Therapeutics employs 10 workers across the globe.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]


MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.